# Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

> **NCT05613426** · PHASE4 · RECRUITING · sponsor: **Henan Institute of Cardiovascular Epidemiology** · enrollment: 330 (estimated)

## Conditions studied

- ST Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** Rosuvastatin 20 mg
- **DRUG:** Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]

## Key facts

- **NCT ID:** NCT05613426
- **Lead sponsor:** Henan Institute of Cardiovascular Epidemiology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613426, "Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05613426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*